Moderna secured a $1.5 billion financing package as part of a plan to reach break‑even by 2028 and to redirect revenue from its seasonal vaccine franchise into oncology and rare disease. At the same time the company announced it is halting development of three clinical mRNA programs and narrowing parts of its pipeline. Moderna says the funding and reprioritization will support higher‑value therapeutic investments and sustained R&D, reflecting a strategic pivot amid tougher market conditions and a shift from pandemic-era demand to diversified long‑term product planning.